INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio (NASDAQ: INMB) narrowed its third-quarter 2026 net loss while advancing Ebstrocel toward a planned UK marketing application.
Net loss was $4.722 million, versus $6.472 million a year earlier; loss per share narrowed to $0.17 from $0.24. Cash totaled $16.329 million at September 30. An October financing raised $4.5 million gross through shares and warrants. The company expects cash resources to fund operations through the third quarter of 2027.
Following its October 20 pre-application submission, INmune Bio targets a complete UK application for Ebstrocel, its treatment candidate for recessive dystrophic epidermolysis bullosa, in early February 2027. It anticipates potential UK approval in mid-2027, subject to validation, review and information requests. A U.S. application is targeted for mid-2027, subject to FDA feedback. A Uniphar agreement establishes a framework for potential international named-patient access.
INmune Bio (INMB) will report third-quarter 2026 financial results and provide a corporate update on November 5, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the quarter ended September 30, 2026. A transcript will follow approximately 24 hours after the scheduled call, and a replay will be available through December 21, 2026.
INmune Bio (NASDAQ: INMB) entered into a definitive financing agreement expected to raise approximately $4.50 million in gross proceeds.
The offering to a single healthcare-focused institutional investor includes 3,000,000 common shares and a concurrent private placement of unregistered warrants to purchase up to 3,000,000 shares. The warrants have a $1.65 exercise price, become exercisable six months after issuance and expire 5.5 years after issuance. Closing is expected on or about October 29, 2026, subject to customary closing conditions. Gross proceeds exclude placement agent fees and other estimated offering expenses.
INmune Bio (INMB) submitted its final UK pre-application package for Ebstrocel to the MHRA on October 20, 2026. The investigational cell therapy targets recessive dystrophic epidermolysis bullosa (RDEB). The company targets a complete marketing application in early February 2027, replacing a rolling submission previously planned to start in late 2026.
INmune Bio believes faster manufacturing progress supports a revised approach that could advance potential UK approval by approximately six weeks to mid-2027, subject to MHRA review. It expects a response within three to six months after submission, subject to validation, review and additional information requests. A U.S. biologics license application is planned for Q2 2027, subject to feedback from a planned FDA Type B meeting; the company is prioritizing the FDA application ahead of an EMA submission.
INmune Bio (NASDAQ: INMB) signed a Master Services Agreement with Uniphar Durbin Ireland to support international access and commercialization of Ebstrocel.
The investigational cell therapy is being developed for recessive dystrophic epidermolysis bullosa (RDEB). INmune Bio initially plans named-patient access, allowing physician requests for individual eligible patients, in selected European countries and the Middle East and North Africa, subject to local law and country-specific statements of work. This pathway may permit access before local marketing approval. Broader distribution depends on securing regulatory approvals, pricing and reimbursement in individual countries; territorial expansion requires mutual agreement. INmune Bio believes using Uniphar’s existing infrastructure offers a capital-efficient alternative to building country-by-country capabilities.
INmune Bio (INMB) and Quantum Computing (QUBT) announced a collaboration to explore potential new applications for INmune Bio's investigational Alzheimer's treatment XPro. The work combines INmune Bio's preclinical research and data from four clinical trials with QCi's Dirac-3S quantum optimization machine, artificial intelligence and conventional analytics. The companies intend to identify treatment-response biomarkers and prioritize potential disease indications, with INmune Bio initially focusing on rare diseases.
The Stage 1 engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets; the agreement includes options for additional work. The companies plan to compare quantum optimization with conventional statistical and machine-learning methods to test where it adds value. They also aim to establish a repeatable discovery process for additional datasets and potential indications.
INmune Bio (INMB) will attend the 2026 Maxim Growth Summit from October 12 to 14 at The Hard Rock Hotel NYC. The company will hold one-on-one meetings with institutional investors and engage with Maxim research analysts. CEO David Moss will present on the Immunology & Inflammation Therapies Panel on October 14 at 10:30 a.m. Portions of the summit will also be streamed online.
INmune Bio (INMB) appointed R. Duane Clark II and James Sapirstein to its Board of Directors to bolster rare-disease commercialization and business-development capabilities as Ebstrocel™ advances toward potential launch.
Clark is General Manager, U.S. Rare Diseases at Sanofi, leading a multi‑billion‑dollar portfolio of seven brands with full profit-and-loss responsibility and extensive experience in market access, launches and M&A integration. Sapirstein brings more than 40 years of biopharma leadership, including six global product launches, founding Tobira Therapeutics and guiding it into a potential $1.7 billion Allergan transaction, and broad transaction, licensing and restructuring experience.
INmune Bio is advancing two late-stage platforms: CORDStrom™, which has shown successful clinical readouts in recessive dystrophic epidermolysis bullosa (RDEB) and is moving toward MAA filings with the UK MHRA in 2026 and EU EMA in 2027 plus a planned U.S. BLA; and XPro1595™, which has FDA Fast Track designation and End-of-Phase 2 regulatory alignment supporting an integrated Phase 2b/3 seamless adaptive registrational program in early Alzheimer’s disease with neuroinflammation.
INmune Bio (INMB) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, with an on-demand presentation available starting September 11, 2026, at 7:00 a.m. ET.
Chief Executive Officer David Moss will host one-on-one meetings with institutional investors and deliver a live presentation on Monday, September 14 at 10:30 a.m. ET. The company highlights two late-stage platforms: CORDStrom™, which is moving to regulatory filing phases with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027 plus a planned U.S. BLA; and XPro1595™, which has FDA Fast Track designation and is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.
INmune Bio (NASDAQ: INMB) has submitted two key regulatory packages to the European Medicines Agency for its investigational therapy Ebstrocel™ in recessive dystrophic epidermolysis bullosa (RDEB): an application for Orphan Drug Designation and a pre-MAA Scientific Advice package.
According to INmune Bio, these filings are intended to support a planned EU Marketing Authorization Application (MAA) in Q1 2027, as part of a coordinated global strategy that also targets a UK MAA in Q4 2026 and a U.S. BLA in Q1 2027. If orphan designation is granted and maintained through approval, the RDEB indication could access development incentives and potentially 10 years of EU market exclusivity, subject to applicable requirements. Ebstrocel is the first disease-specific product from the company’s CORDStrom™ pooled, allogeneic umbilical cord-derived mesenchymal stromal cell platform, which is designed to deliver scalable, off-the-shelf therapies.